For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/UBN865. CME credit will be available until January 29, 2025.
Changing Disease Course for Patients With Pulmonary Hypertension: Expert Insights on Improving Diagnosis and Novel Approaches to Treat the Underlying Causes
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Merck & Co., Inc.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Vallerie V. McLaughlin, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Aerami Therapeutics Holdings, Inc.; Aerovate Therapeutics, Inc.; Caremark LLC; CorVista Health, Inc.; Enzyvant Therapeutics GmbH; Gossamer Bio; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; United Therapeutics Corporation; and Vertex Pharmaceuticals Incorporated.
Grant/Research Support from Aerovate Therapeutics, Inc.; Enzyvant Therapeutics GmbH; Gossamer Bio; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; SoniVie.
Co-Chair/Planner
Ioana R. Preston, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Aerovate Therapeutics, Inc.; Gossamer Bio; Janssen Pharmaceuticals, Inc.; Liquidia Corporation; Merck & Co., Inc.; and United Therapeutics Corporation.
Grant/Research Support from Bellerophon Therapeutics; Janssen Pharmaceuticals, Inc.; Liquidia Corporation; Merck & Co., Inc.; and United Therapeutics Corporation.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
View all episodes
By PVI, PeerView Institute for Medical Education
5
33 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/UBN865. CME credit will be available until January 29, 2025.
Changing Disease Course for Patients With Pulmonary Hypertension: Expert Insights on Improving Diagnosis and Novel Approaches to Treat the Underlying Causes
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Merck & Co., Inc.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Vallerie V. McLaughlin, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Aerami Therapeutics Holdings, Inc.; Aerovate Therapeutics, Inc.; Caremark LLC; CorVista Health, Inc.; Enzyvant Therapeutics GmbH; Gossamer Bio; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; United Therapeutics Corporation; and Vertex Pharmaceuticals Incorporated.
Grant/Research Support from Aerovate Therapeutics, Inc.; Enzyvant Therapeutics GmbH; Gossamer Bio; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; SoniVie.
Co-Chair/Planner
Ioana R. Preston, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Aerovate Therapeutics, Inc.; Gossamer Bio; Janssen Pharmaceuticals, Inc.; Liquidia Corporation; Merck & Co., Inc.; and United Therapeutics Corporation.
Grant/Research Support from Bellerophon Therapeutics; Janssen Pharmaceuticals, Inc.; Liquidia Corporation; Merck & Co., Inc.; and United Therapeutics Corporation.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
5 Listeners
3 Listeners
3 Listeners
11 Listeners
5 Listeners
28 Listeners
9 Listeners
3 Listeners
2 Listeners
4 Listeners
3 Listeners
5 Listeners
5 Listeners
2 Listeners
0 Listeners
9 Listeners
2 Listeners
12 Listeners
2 Listeners